Polina Sysa-Shah1, Carlo G Tocchetti2, Manveen Gupta3, Peter P Rainer4, Xiaoxu Shen5, Byung-Hak Kang6, Frances Belmonte1, Jian Li7, Yi Xu1, Xin Guo1, Djahida Bedja1, Wei Dong Gao5, Nazareno Paolocci8, Rutwik Rath9, Douglas B Sawyer9, Sathyamangla V Naga Prasad3, Kathleen Gabrielson10. 1. Department of Molecular and Comparative Pathobiology, Johns Hopkins Medical Institutions, MRB 807, 733 N. Broadway, Baltimore, MD 21205, USA. 2. Division of Internal Medicine, Department of Translational Medical Sciences, Federico II University, Naples, Italy. 3. Department of Molecular Cardiology, Cleveland Clinic, Lerner Research Institute, Cleveland, OH, USA. 4. Division of Cardiology, Department of Medicine, Medical University of Graz, Graz, Austria Division of Cardiology, Department of Medicine, Johns Hopkins Medical Institutions, Baltimore, MD, USA. 5. Department of Anesthesiology and Critical Care Medicine, Johns Hopkins Medical Institutions, Baltimore, MD, USA. 6. Department of Oncology, Johns Hopkins Medical Institutions, Baltimore, MD, USA. 7. Clinical Laboratory, Chinese PLA General Hospital, Beijing, China. 8. Division of Cardiology, Department of Medicine, Johns Hopkins Medical Institutions, Baltimore, MD, USA. 9. Cardiovascular Services, Maine Medical Center, Portland, ME, USA. 10. Department of Molecular and Comparative Pathobiology, Johns Hopkins Medical Institutions, MRB 807, 733 N. Broadway, Baltimore, MD 21205, USA kgabriel@jhmi.edu.
Abstract
AIMS: Despite the observation that ErbB2 regulates sensitivity of the heart to doxorubicin or ErbB2-targeted cancer therapies, mechanisms that regulate ErbB2 expression and activity have not been studied. Since isoproterenol up-regulates ErbB2 in kidney and salivary glands and β2AR and ErbB2 complex in brain and heart, we hypothesized that β-adrenergic receptors (AR) modulate ErbB2 signalling status. METHODS AND RESULTS: ErbB2 transfection of HEK293 cells up-regulates β2AR, and β2AR transfection of HEK293 up-regulates ErbB2. Interestingly, cardiomyocytes isolated from myocyte-specific ErbB2-overexpressing (ErbB2(tg)) mice have amplified response to selective β2-agonist zinterol, and right ventricular trabeculae baseline force generation is markedly reduced with β2-antagonist ICI-118 551. Consistently, receptor binding assays and western blotting demonstrate that β2ARs levels are markedly increased in ErbB2(tg) myocardium and reduced by EGFR/ErbB2 inhibitor, lapatinib. Intriguingly, acute treatment of mice with β1- and β2-AR agonist isoproterenol resulted in myocardial ErbB2 increase, while inhibition with either β1- or β2-AR antagonist did not completely prevent isoproterenol-induced ErbB2 expression. Furthermore, inhibition of ErbB2 kinase predisposed mice hearts to injury from chronic isoproterenol treatment while significantly reducing isoproterenol-induced pAKT and pERK levels, suggesting ErbB2's role in transactivation in the heart. CONCLUSION: Our studies show that myocardial ErbB2 and βAR signalling are linked in a feedback loop with βAR activation leading to increased ErbB2 expression and activity, and increased ErbB2 activity regulating β2AR expression. Most importantly, ErbB2 kinase activity is crucial for cardioprotection in the setting of β-adrenergic stress, suggesting that this mechanism is important in the pathophysiology and treatment of cardiomyopathy induced by ErbB2-targeting antineoplastic drugs. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: Despite the observation that ErbB2 regulates sensitivity of the heart to doxorubicin or ErbB2-targeted cancer therapies, mechanisms that regulate ErbB2 expression and activity have not been studied. Since isoproterenol up-regulates ErbB2 in kidney and salivary glands and β2AR and ErbB2 complex in brain and heart, we hypothesized that β-adrenergic receptors (AR) modulate ErbB2 signalling status. METHODS AND RESULTS:ErbB2 transfection of HEK293 cells up-regulates β2AR, and β2AR transfection of HEK293 up-regulates ErbB2. Interestingly, cardiomyocytes isolated from myocyte-specific ErbB2-overexpressing (ErbB2(tg)) mice have amplified response to selective β2-agonist zinterol, and right ventricular trabeculae baseline force generation is markedly reduced with β2-antagonist ICI-118 551. Consistently, receptor binding assays and western blotting demonstrate that β2ARs levels are markedly increased in ErbB2(tg) myocardium and reduced by EGFR/ErbB2 inhibitor, lapatinib. Intriguingly, acute treatment of mice with β1- and β2-AR agonist isoproterenol resulted in myocardial ErbB2 increase, while inhibition with either β1- or β2-AR antagonist did not completely prevent isoproterenol-induced ErbB2 expression. Furthermore, inhibition of ErbB2 kinase predisposed mice hearts to injury from chronic isoproterenol treatment while significantly reducing isoproterenol-induced pAKT and pERK levels, suggesting ErbB2's role in transactivation in the heart. CONCLUSION: Our studies show that myocardial ErbB2 and βAR signalling are linked in a feedback loop with βAR activation leading to increased ErbB2 expression and activity, and increased ErbB2 activity regulating β2AR expression. Most importantly, ErbB2 kinase activity is crucial for cardioprotection in the setting of β-adrenergic stress, suggesting that this mechanism is important in the pathophysiology and treatment of cardiomyopathy induced by ErbB2-targeting antineoplastic drugs. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Gregory M Cote; Thomas A Miller; Nathan K Lebrasseur; Yukio Kuramochi; Douglas B Sawyer Journal: Exp Cell Res Date: 2005-09-26 Impact factor: 3.905
Authors: Peter Nagy; György Vereb; Zsolt Sebestyén; Gábor Horváth; Stephen J Lockett; Sándor Damjanovich; John W Park; Thomas M Jovin; János Szöllosi Journal: J Cell Sci Date: 2002-11-15 Impact factor: 5.285
Authors: Iván P Uray; John H Connelly; Vilmos Thomázy; Gregory L Shipley; William K Vaughn; O Howard Frazier; Heinrich Taegtmeyer; Peter J A Davies Journal: J Heart Lung Transplant Date: 2002-07 Impact factor: 10.247
Authors: Carrie G Lenneman; Wissam M Abdallah; Holly M Smith; Vandana Abramson; Ingrid A Mayer; Cheri Silverstein; Cheri Silverstein; Julie Means-Powell; Sachin Y Paranjape; Daniel Lenihan; Douglas B Sawyer; Satish R Raj Journal: Ecancermedicalscience Date: 2014-07-17
Authors: Bat-Erdene Myagmar; James M Flynn; Patrick M Cowley; Philip M Swigart; Megan D Montgomery; Kevin Thai; Divya Nair; Rumita Gupta; David X Deng; Chihiro Hosoda; Simon Melov; Anthony J Baker; Paul C Simpson Journal: Circ Res Date: 2017-02-20 Impact factor: 17.367
Authors: Akshay Shekhar; Xianming Lin; Fang-Yu Liu; Jie Zhang; Huan Mo; Lisa Bastarache; Joshua C Denny; Nancy J Cox; Mario Delmar; Dan M Roden; Glenn I Fishman; David S Park Journal: J Clin Invest Date: 2016-10-24 Impact factor: 14.808
Authors: Shuchi Guo; Ama Dedo Okyere; Erin McEachern; Joshua L Strong; Rhonda L Carter; Viren C Patwa; Toby P Thomas; Melissa Landy; Jianliang Song; Ana Maria Lucchese; Thomas G Martin; Erhe Gao; Sudarsan Rajan; Jonathan A Kirk; Walter J Koch; Joseph Y Cheung; Douglas G Tilley Journal: Cardiovasc Res Date: 2022-03-25 Impact factor: 13.081
Authors: Gilda Varricchi; Pietro Ameri; Christian Cadeddu; Alessandra Ghigo; Rosalinda Madonna; Giancarlo Marone; Valentina Mercurio; Ines Monte; Giuseppina Novo; Paolo Parrella; Flora Pirozzi; Antonio Pecoraro; Paolo Spallarossa; Concetta Zito; Giuseppe Mercuro; Pasquale Pagliaro; Carlo G Tocchetti Journal: Front Physiol Date: 2018-03-07 Impact factor: 4.566
Authors: Sathyamangla V Naga Prasad; Manveen K Gupta; Zhong-Hui Duan; Venkata Suresh K Surampudi; Chang-Gong Liu; Ashwin Kotwal; Christine S Moravec; Randall C Starling; Dianne M Perez; Subha Sen; Qingyu Wu; Edward F Plow; Sadashiva Karnik Journal: PLoS One Date: 2017-03-22 Impact factor: 3.240
Authors: Anita Boyd; Paul Stoodley; David Richards; Rina Hui; Paul Harnett; Kim Vo; Tom Marwick; Liza Thomas Journal: PLoS One Date: 2017-04-13 Impact factor: 3.240